Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
about
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsDefining normoxia, physoxia and hypoxia in tumours-implications for treatment responseMultimodal imaging guided preclinical trials of vascular targeting in prostate cancer.Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostateA novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cellsAndrogen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling.Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo.Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistanceThe unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1PKM2 and HIF-1α regulation in prostate cancer cell lines
P2860
Q26774750-2CF1DDE1-EDB3-464C-8226-81E3CDEEF147Q27009437-C1159356-F394-4D49-80C3-17F8E1BBB76FQ30393012-4DC07992-3B29-435D-8E0C-0A9C16D68270Q35095977-B1C39E08-A703-48A9-8882-2880A96AFCCFQ35781567-91F6E2DF-FDBE-4E79-A8E4-9825EC3B3763Q36707740-D0C55229-66DA-4028-8544-10283042AD00Q37295602-501B43D0-DD96-45C2-8210-C9A3B65826CCQ38844346-796C8E36-B336-4740-BFE6-A8FDEF9C33F8Q38851486-12C9A349-3732-43AA-9C21-4612710A2FC6Q41314252-F92EF422-C90A-40A7-A038-CD8BA2CB12CCQ47763534-93B96B41-FC25-4A39-99C1-82EF03B3E3C8Q48371418-C10AE3C0-F3B2-483D-8AE6-807CB677923DQ58692417-61036F6C-F747-4FF3-811F-FBEE56CAD095Q58741231-77ED8692-C93C-4451-A306-FCBDEA854C51
P2860
Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Androgen deprivation results i ...... N improves treatment response.
@en
Androgen deprivation results i ...... N improves treatment response.
@nl
type
label
Androgen deprivation results i ...... N improves treatment response.
@en
Androgen deprivation results i ...... N improves treatment response.
@nl
prefLabel
Androgen deprivation results i ...... N improves treatment response.
@en
Androgen deprivation results i ...... N improves treatment response.
@nl
P2093
P2860
P356
P1476
Androgen deprivation results i ...... 4N improves treatment response
@en
P2093
Christopher A Mitchell
Claire Ward
Jenny Worthington
Louise Ming
Niall M Byrne
Sarah Nicole Camac
Stephanie R McKeown
P2860
P304
P356
10.1002/IJC.27796
P577
2012-11-23T00:00:00Z